Existing backer GV returned to take part in a $100m round for the clinical data software provider that also attracted new investor Regeneron Pharmaceuticals.
US-based health informatics technology developer DNAnexus closed a $100m funding round yesterday backed by biotechnology firm Regeneron Pharmaceuticals and GV, an early-stage investment subsidiary of internet and technology conglomerate Alphabet.
Investment management firm Perceptive Advisors and venture capital firm Northpond Ventures co-led the round, which also featured Foresite Capital, TPG Capital and First Round Capital.
Founded in 2009, DNAnexus has created a software platform that enables researchers to store, analyse, manage and collaborate on large amounts of complex clinical data…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
